Prospective Observational study of Sitagliptin in Subjects with type 2 Diabetes and Chronic Renal Failure

Prospective Observational study of Sitagliptin in Subjects with type 2 Diabetes and Chronic Renal Failure - POSEIDON Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016645

Enrollment

Registered

2015-02-26

Start date

2013-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients with chronic renal failure who were newly started sitagliptin administration from Nov. 1st in 2013

Exclusion criteria

Exclusion criteria: 1) Hypersensitivity to sitagliptin 2) Patients who had severe ketosis or diabetic coma within 6 months 3) Severe infection or trauma, perioperative 4) Receiving glinide therapy 5) Patients whose participation is deemed inappropriate at the discretion of the attending physician

Design outcomes

Primary

Measure	Time frame
Changes in the HbA1c or glycated albumin level at 3 and 6 months after sitagliptin treatment initiation. Adverse events including hypoglycemia and those rates of occurrence	—

Countries

Japan

Contacts

Public ContactKenro Nishida

Kumamoto Chuo Hospital Department of Diabetes and Endocrinology

knihida@orange.ocn.ne.jp096-370-3111

Outcome results